GN-15 R15: Singapore Medical Device Registration Guidance

1. Key takeaways

GN-15, Guidance on Medical Device Product Registration, is the master guidance for medical device registration in Singapore; the current version is Revision 15 (R15, October 2026). It sets out classification and registration requirements, the four registration pathways of Immediate / Expedited / Abridged / Full, the rules on reference agency recognition, the submission documentation requirements, and the annual retention fee and overdue cancellation rules (Section 12). It is supported by four annex templates: Annex 1, the Letter of Authorisation; Annex 2, the Marketing History Declaration; Annex 3, the Safety Declaration; and Annex 4, the Label/AE/FSCA Declaration. Because GN-15 governs every registration pathway and every annex template an applicant will touch, treating it as the anchor document of any Singapore project is not optional — it is the reference against which all other guidance is read.

• The current version is GN-15 R15 (October 2026), after three updates within 2026.
• Section 3 governs classification and registration requirements, including the Class A exemption at Section 3.1; Sections 4–6 cover the pathways and reference agencies; Section 12 covers retention fees and cancellation.
• R14 added Annex 4, which makes disclosure of labelling differences and AE/FSCA history an active submission duty.
• R13 introduced reliance on Malaysian MDA registrations, potentially qualifying such products for the Abridged pathway.

2. Legal basis

The table below consolidates the version history, annex set and key sections of GN-15 that determine how a registration is prepared and maintained.

The pace of revision matters as much as the content: within a single year the operative text changed three times, which means that any internal template, checklist or training material built on an earlier revision silently degrades until it is re-verified against R15 and the HSA guidance documents page.

3. Expert insights

Insight 1: Three revisions in one year is the most notable regulatory phenomenon in Singapore for 2026. GN-15 went through R13 (10 March) → R14 (14 September) → R15 (October) within 2026. Of the Chinese-language materials we have checked, the vast majority still reference earlier versions. A quick way to judge whether a service provider genuinely works on Singapore matters is to ask it: which revision is GN-15 now at, and what is Annex 4? Anyone who cannot answer should have the currency of their materials questioned. Version currency is a proxy for engagement: a team that tracks revisions in the same year they are issued is a team that is filing, while a team relying on a two-year-old summary is not.

Insight 2: Annex 4, added by R14, is the most operationally consequential new item of 2026. According to industry compilation (the specific provisions are subject to the official HSA GN-15 R15 text), Annex 4, the Device Labelling, AE and FSCA Declaration added by R14, contains requirements in two parts:

• Part 1: applications submitted through the Abridged / Expedited / Immediate pathways must disclose the differences between the Singapore label and the label approved by the reference agency;
• Part 2: all applications must disclose the history of reportable adverse events (AE) and field safety corrective actions (FSCA).

The substantive effect of this requirement is that the historical safety record changes from something answered only when asked into something that must be declared proactively. Products with an overseas recall or vigilance history must now state it clearly at the time of submission. This rewards preparation: a company that has already assembled its AE/FSCA history and drafted explanations of remediation can turn disclosure into a demonstration of control, while an unprepared applicant meets the question for the first time in front of the reviewer.

Insight 3: The R13 reliance on the Malaysian MDA is real, tangible regional leverage. According to industry compilation (subject to the official HSA text), R13 introduced reliance on registrations by Malaysia’s Medical Device Authority (MDA): where a Class B/C/D device has been registered by MDA after full conformity assessment by its recognised agency, and the labelled use is consistent with the intended use in Singapore, the product may qualify for the Abridged pathway. For manufacturers already positioned in Southeast Asia, this is a channel that converts a Malaysian asset into a Singapore acceleration (see Chapter 17 for detail). The conditions matter, though: the conformity assessment must be full rather than abridged, and the labelled use must match, so the qualification should be verified line-by-line before it is promised to management as a timeline.

Insight 4: The annexes are format requirements, not reference examples. The four GN-15 annexes are templates, and HSA expects applicants to issue them in the prescribed form. In document preparation we apply the templates strictly, especially the Annex 1 Letter of Authorisation — self-drafted versions are routinely sent back for supplementation. The practical rule is simple: use the current R15 annex files as downloaded from HSA, complete every field they contain, and treat any deviation as a deliberate, documented decision rather than an accident of drafting.

4. Practical recommendations

• First step at project initiation: verify the version. Confirm the current version number of GN-15 on the HSA guidance documents page and download all annex templates.
• Maintain a version change log: record the effective date of every GN update and its impact on your project.
• Annex 4 requires manufacturer cooperation: only the Product Owner holds the AE/FSCA history, so request it from the manufacturer early in document preparation to avoid discovering the gap just before submission.
• Prepare a strategy in advance for products with overseas recall history: proactive disclosure with an explanation of corrective actions is more favourable than being discovered passively.

5. Verification checklist

• □ The current version number of GN-15 has been confirmed on the HSA guidance documents page
• □ The four annex templates have been downloaded and applied
• □ The section requirements for the intended pathway (Sections 4–6) have been confirmed
• □ The AE/FSCA history has been requested from the manufacturer (Annex 4 Part 2)
• □ Where Abridged/Expedited/Immediate is used, the labelling difference statement has been prepared (Annex 4 Part 1)
• □ A GN version change log has been established

Regulatory information verified as of: 26 October 2026

Source level: Tier 2 (HSA guidance documents page, GN-15 R15), Tier 3 (compilation of the specific provisions of the R13/R14 revisions, marked as pending verification against the official text)

How GRZAN can help. GRZAN provides medical device and IVD registration, quality system, authorised representative and local testing support across Southeast Asia, including Singapore. Our team prepares dossiers to ASEAN CSDT structure, manages submissions and deficiency responses with HSA, and supports post-market vigilance obligations. Business enquiries: info@grzanglobal.com